News

According to Dov, the reorganization is designed to maximize the value of the biopharmaceutical company’s existing pipeline and explore and pursue what it describes as “attractive financing opportunities.”

The data, published in the Journal of Clinical Oncology, demonstrated a median time to disease progression (TTP) for the 31 evaluable patients in the trial of 13.5 months.

The scientists at the University of Florida’s McKnight Brain Institute observed that when embryonic stem cells from mice were plated on four different surfaces in cell culture dishes,

Post-operative atrial fibrillation (AF) is the most common complication associated with the approximately 500,000 coronary artery bypass grafting and cardiac valve replacement surgeries performed each year. The company’s

ABIO 08/01 is the first in a new class of non-addictive drugs, different from anxiolytic sedatives, and is being developed to treat clinical anxiety states such as panic

The company is attempting to take advantage of an FDA scheme that extends a product’s period of exclusivity if a company conducts tests to prove the safety and

The product candidate is currently in clinical development for the treatment of chronic middle ear infection, and is also showing potential in other indications such as sinusitis and

The drug was also shown to be effective with a favorable safety profile in three pivotal studies published in the Journal of the American Medical Association. Data show

The company filed for the commencement of insolvency proceedings at a court in Wurzburg, Germany, stating that the adverse reactions caused by TGN1412 in the phase I trial